KU-0059436 (AZD2281)(PARP inhibitor) + Carboplatin + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + Carboplatin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Triple Negative Metastatic Breast Cancer
Conditions
Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin, Paclitaxel
Trial Timeline
Jun 22, 2007 → Apr 11, 2024
NCT ID
NCT00516724About KU-0059436 (AZD2281)(PARP inhibitor) + Carboplatin + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + Carboplatin
KU-0059436 (AZD2281)(PARP inhibitor) + Carboplatin + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + Carboplatin is a phase 1 stage product being developed by AstraZeneca for Triple Negative Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00516724. Target conditions include Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00516724 | Phase 1 | Completed |
Competing Products
20 competing products in Triple Negative Metastatic Breast Cancer